Are you Dr. Biernat?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 13 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
60 Commercial St
Suite 401
Concord, NH 03301Phone+1 603-228-7555
Summary
- Dr. Lukasz Biernat, MD is a board certified internist in Concord, New Hampshire. He is currently licensed to practice medicine in New Hampshire and Ohio.
Education & Training
Hackensack University Medical Center (Mountainside)Residency, Internal Medicine, 2005 - 2008
Medical University of SilesiaClass of 2001
Certifications & Licensure
OH State Medical License 2011 - 2025
NH State Medical License 2008 - 2018- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
- Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2011-2014
- Join now to see all
Clinical Trials
- Safety and Pharmacokinetics Study of Redosing EXPAREL in Healthy Volunteers Start of enrollment: 2014 Aug 01
- A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation Start of enrollment: 2016 Feb 01
Publications & Presentations
PubMed
- 15 citationsPharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers.David C. Rice, Justin W. Heil, Lukasz Biernat
Clinical Drug Investigation. 2017-01-25 - 22 citationsDrug-induced liver damage -- a three-year study of patients from one gastroenterological department.Marek Hartleb, Lukasz Biernat, Anna Kochel
Medical Science Monitor. 2002-04-01 - 4 citationsA randomized, double-blind, placebo controlled, phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of LB-102, a selective dopamine D/5-H...Lukasz Biernat, Vincent T Grattan, Mark S Hixon, Zachary Prensky, Andrew R Vaino
Psychopharmacology. 2022-09-01
Professional Memberships
- Member
